Clinical case of management with intravitreal injection of Ranibizumab (Lucentis®) on AMD predominant occult CNV: 6-Month follow-up with FA, ICG-A, and OCT;Traitement par injection intra-vitréenne de Ranibizumab (Lucentis®) pour des néovaisseaux choroïdiens occultes prédominants liés à la DMLA: Étude et suivi par imagerie en fluorescéine, infracyanine et OCT pendant 6 mois

Journal Francais d'Ophtalmologie

Volumn 29, Issue 7, 2006, Pages 731-737

  Coscas, G ^a,b   Coscas, F ^a,b   Soubrane, G ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Centre de l Odéon   (France)

Author keywords

AMD; Intravitreal injection; Minimally classic; Ranibizumab

Indexed keywords

CYANINE DYE; RANIBIZUMAB;

AGED; ARTICLE; CASE REPORT; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; IMAGING; REMISSION; RETINA MACULA AGE RELATED DEGENERATION; SCANNING LASER OPHTHALMOSCOPE; SUBRETINAL NEOVASCULARIZATION; SYMPTOM; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33748909345     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(06)73842-6     Document Type: Article

References (12)

1. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol, 1991;9:1242-5.
2. Coscas G, Soubrane G. Photocoagulation des néovaisseaux sous rétiniens de la dégénérescence maculaire sénile : résultats d'une étude randomisée de 60 cas. Bull Mem Soc Fr Ophtalmol, 1983;94:1013-22.
3. Bessler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degenaration with verteporfin: two-years results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207.
4. Pieramici DJ, Bressler SB, Koester JM, Bressler NM. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4. Arch Ophthalmol, 2006;24:660-4.
5. Eter N, Krohne TU, Holz FG. New pharmacologic approaches to therapy for age-related macular degeneration. Bio Drugs, 2006;20:167-79.
6. Fraunfelder FW. Pegaptanib for wet macular degeneration. Ophthalmology, 2005;12:1048-53.
7. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci, 2005;46:726-33.
8. Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, et al. Safety and efficacy of intravitreal injection of Ranibizumab in combination with Verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol, 2005;23:509-16.
9. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology, 2006;113:642.e1-4.
10. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology, 2005;112:1048-53.
11. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of Ranibizumab (Lucentis®) for neovascular age-related macular degeneration. Ophthalmology, 2006;13:632.
12. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, et al. Maximum tolerated dose of a humanized antivascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology, 2005;112:1048-53.